|
Article Excerpt
OXiGENE, Inc., Waltham, Mass., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has begun dosing patients in a randomized, double-blinded, controlled Phase II study of its potential first-in-class vascular disrupting agent (VDA), ZYBRESTAT(tm) (fosbretabulin), in combination with the anti-angiogenic drug, bevacizumab, and the chemotherapeutic agents carboplatin and paclitaxel as first-line therapy for patients with Stage IIIb/IV non-small cell lung cancer (NSCLC).
The multi-center study is being conducted in...
|
|
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
